Quarterly revenue has collapsed 94% from $54.2M in 2024Q4 to $3.3M in 2026Q2 with erratic gross margins swinging between -99.2% and 100%, while operating losses persist at -$24.4M despite R&D cuts of 64%.
Alector, Inc. (ALEC) annual income statement — 10-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 173.47M | 21.05M | 100.56M | 97.06M | 133.62M | 207.09M | 21.1M | 21.22M | 27.68M | 3.73M | 416K |
| Revenue Growth % | 151.23% | -79.07% | 3.6% | -27.36% | -35.48% | 881.54% | -0.57% | -23.33% | 641.02% | 797.84% | - |
| Cost of Goods Sold | 0 | 9.66M | 185.94M | 8.85M | 0 | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| COGS % of Revenue | - | 45.91% | 184.91% | 9.12% | - | 91.46% | 743.53% | 473.76% | 263.87% | 800.83% | 3287.02% |
| Gross Profit | 10.6M | 11.38M | -85.38M | 88.21M | 133.62M | 17.68M | -135.77M | -79.31M | -45.35M | -26.18M | -13.26M |
| Gross Margin % | 6.11% | 54.09% | -84.91% | 90.88% | 100% | 8.54% | -643.53% | -373.76% | -163.87% | -700.83% | -3187.02% |
| Gross Profit Growth % | - | 113.33% | -196.79% | -33.98% | 655.84% | 113.02% | -71.19% | -74.87% | -73.27% | -97.44% | - |
| Operating Expenses | 138.51M | 157.19M | 59.62M | 239.95M | 271.45M | 55.04M | 59.4M | 35.09M | 84.97M | 36.41M | 15.55M |
| OpEx % of Revenue | - | 746.93% | 59.28% | 247.22% | 203.16% | 26.58% | 281.56% | 165.39% | 306.99% | 974.94% | 3737.5% |
| Selling, General & Admin | 38.69M | 53.99M | 57.41M | 56.69M | 61.03M | 55.04M | 59.4M | 33.94M | 11.93M | 6.5M | 1.87M |
| SG&A % of Revenue | - | 256.53% | 57.09% | 58.4% | 45.68% | 26.58% | 281.56% | 159.94% | 43.12% | 174.11% | 450.48% |
| Research & Development | 99.81M | 123.06M | 209.24M | 192.12M | 210.42M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| R&D % of Revenue | - | 584.77% | 208.08% | 197.93% | 157.48% | 91.46% | 743.53% | 473.76% | 263.87% | 800.83% | 3287.02% |
| Other Operating Expenses | 0 | -19.86M | -207.03M | -8.85M | 0 | -189.41M | -156.87M | -99.37M | 5.04M | 199K | 22K |
| Operating Income | 34.96M | -145.81M | -145M | -151.74M | -137.83M | -37.36M | -195.17M | -114.4M | -57.29M | -32.68M | -15.13M |
| Operating Margin % | 20.16% | -692.83% | -144.19% | -156.33% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -874.94% | -3637.5% |
| Operating Income Growth % | - | -0.56% | 4.44% | -10.09% | -268.93% | 80.86% | -70.6% | -99.7% | -75.31% | -115.96% | - |
| EBITDA | 39.26M | -136.15M | -136.16M | -142.89M | -129.36M | -29.05M | -187.91M | -108.83M | -56.27M | -32M | -14.93M |
| EBITDA Margin % | 22.63% | -646.93% | -135.4% | -147.22% | -96.82% | -14.03% | -890.65% | -512.89% | -203.31% | -856.73% | -3589.18% |
| EBITDA Growth % | 133.86% | 0.01% | 4.71% | -10.46% | -345.38% | 84.54% | -72.66% | -93.41% | -75.85% | -114.31% | - |
| D&A (Non-Cash Add-back) | 4.3M | 9.66M | 8.84M | 8.85M | 8.47M | 8.31M | 7.26M | 5.57M | 1.02M | 680K | 201K |
| EBIT | -82.89M | -142.76M | -118.92M | -125.18M | -130.06M | -36.33M | -195.17M | -113.25M | -57.29M | -32.68M | -15.13M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 6.81M | 3.05M | 26.08M | 26.56M | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199K | 22K |
| Pretax Income | 41.77M | -142.76M | -118.92M | -125.18M | -130.06M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Pretax Margin % | 24.08% | -678.36% | -118.26% | -128.97% | -97.33% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3632.21% |
| Income Tax | 358K | 168K | 128K | 5.21M | 3.25M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.86% | -0.12% | -0.11% | -4.16% | -2.5% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 41.41M | -142.93M | -119.05M | -130.39M | -133.31M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Net Margin % | 23.87% | -679.16% | -118.39% | -134.34% | -99.77% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3632.21% |
| Net Income Growth % | 138.44% | -20.06% | 8.7% | 2.19% | -266.95% | 80.9% | -80.51% | -101.7% | -60.86% | -114.96% | - |
| Net Income (Continuing) | 41.41M | -142.93M | -119.05M | -130.39M | -133.31M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.37 | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | -1.62 | -0.76 | -0.63 | -1.78 |
| EPS Growth % | 133.61% | -13.01% | 21.15% | 3.7% | -260% | 81.63% | -51.23% | -113.16% | -20.63% | 64.61% | - |
| EPS (Basic) | - | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | -1.62 | -0.76 | -0.63 | -1.78 |
| Diluted Shares Outstanding | 111.22M | 103M | 96.59M | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 8.5M |
| Basic Shares Outstanding | 111.22M | 103M | 96.59M | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 8.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ALEC stock.
For fiscal year 2025, Alector, Inc. (ALEC) reported total revenue of $21.0M. This represents a 4958.9% increase compared to $0.4M in 2016.
Alector, Inc. (ALEC) reported a net loss of $142.9M for the fiscal year ending 2025.
Alector, Inc. (ALEC) reported an operating income of $-145.8M, resulting in an operating profit margin of -692.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Alector, Inc. (ALEC) generated $11.4M in gross profit for the year, representing a gross profit margin of 54.1%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Collapsed revenue base sustainability
Metrics are mathematically derived from official filings.
Revenue Base Collapses Toward Zero
Based on Alector's reported income statements, quarterly revenue has imploded from $54.2M in 2024Q4 to $3.3M in 2026Q2, with year-over-year declines of 57.8% to 88.5% across the last four quarters, suggesting collaboration-driven revenue has effectively vanished.
The trajectory is not a cyclical dip but an apparent structural loss of the revenue engine: the top line has fallen from roughly $15M per quarter in early 2024, spiked to $54.2M in 2024Q4, and then collapsed to single-digit millions. Growth rates of -76.9%, -78.8% and -88.5% across 2025 indicate the $54M quarter was almost certainly a one-time recognition event rather than a durable run-rate, so investors should not extrapolate any organic recovery absent a newly disclosed revenue source. The remaining $1-3M quarterly prints appear too small to materially fund the current operating cost structure.
Gross Margin Swings Signal Cost Distortions
According to ALEC's quarterly filings, gross margin swung from 85.6% in 2024Q1 to -99.2% in 2026Q1 as COGS of $33.6M dwarfed $3.7M of revenue, then snapped back to 100% in 2026Q2 when COGS printed zero, an unusual pattern warranting investigation of inventory or cost recognition.
A biotech with minimal product revenue should not be printing $27-46M quarterly COGS, which suggests these charges reflect inventory write-downs, manufacturing commitment losses or cost realignment tied to a discontinued program rather than true cost of goods. That interpretation matters because the apparent margin 'recovery' to 100% in 2026Q2 is an artifact of zero recorded COGS, not evidence of pricing power or operating efficiency. Until revenue rebuilds at scale, gross margin is analytically meaningless for ALEC and should be excluded from any peer comparison with commercial-stage names like ACAD at 91.7%.
2024Q4: A One-Quarter Earnings Mirage
As reported in ALEC's SEC filings, the fourth quarter of 2024 marks the clearest inflection: $54.2M of revenue compressed the operating loss to just -$7.2M and the net loss to -$2.1M, before revenue collapsed and losses re-widened to roughly -$24M per quarter thereafter.
The 2024Q4 print, with EPS of only -$0.02 versus -$0.34 to -$0.44 in surrounding quarters, would have supported a near-breakeven narrative had it persisted; its immediate reversal in 2025Q1 suggests the market's implied valuation at that time may have been anchored to an unsustainable revenue event. The lasting impact is that ALEC's baseline economics are now laid bare: roughly -$24M of quarterly operating loss on de minimis revenue. This inflection is the single most important period for modeling forward losses because it defines both the pre-collapse and post-collapse cost regimes.
Deep Retrenchment Cuts Burn by Half
Based on Alector's reported figures, quarterly R&D has fallen from $53.5M in 2024Q3 to $19.5M in 2026Q2 and SG&A from $15.8M to $8.3M, reductions of roughly 64% and 47% that have nonetheless failed to close the operating loss.
The scale and speed of the cuts imply pipeline prioritization, likely the discontinuation or out-licensing of programs that were consuming capital in 2024; R&D now constitutes about 59% of the combined R&D-plus-SG&A stack, still the dominant cost line and the primary lever management retains. However, the operating loss only narrowed from -$48.4M (2024Q3) to -$24.4M (2026Q2), meaning cost discipline has offset roughly half of the lost revenue rather than restored balance, so further reductions may be needed to extend runway. Investors should monitor whether SG&A stabilizes near $8M, which would suggest the remaining overhead approximates a true holding-company floor.
Shrinking SBC Improves Loss Quality
According to ALEC's reported filings, stock-based compensation has fallen from $10.3M in 2024Q1 to $2.6M in 2026Q2, a 75% reduction that materially improves the quality of the loss base, while net losses have consistently run smaller than operating losses, implying recurring non-operating income cushions the bottom line.
The declining SBC trajectory is a genuine positive for loss quality, as it indicates management is not papering over operating deterioration with equity issuance at prior run-rates; SBC represented over 25% of the operating loss in 2024 but only about 11% in 2026Q2. Separately, the persistent gap between operating and net losses (for example -$24.4M versus -$23.0M in 2026Q2) suggests interest income or other non-operating items are providing a modest, likely interest-rate-sensitive offset, which could compress if cash balances are drawn down. Because these non-operating components are not itemized in the supplied data, the durability of that cushion warrants further investigation in the full filings.
Cost Structure Outlasts Revenue Runway
As reported in recent SEC filings, despite cutting R&D by 64%, Alector still posted a -$24.4M operating loss in 2026Q2 on $3.3M of revenue, suggesting the cost structure remains anchored to a pipeline scale that current revenue no longer supports.
A short-seller would argue that the 2026Q2 'improvement' is largely cosmetic: the sequential narrowing from -$39.6M in 2025Q4 is driven by expensing discipline and the disappearance of large COGS charges, not by any recovering commercial franchise, leaving roughly $96M of annualized operating loss to be funded externally. Peer benchmarks sharpen the concern — ACAD converts a $1.1B revenue base into 9.8% operating margins, while ALEC's negative gross profit in six of ten quarters indicates no path to comparable economics without a new revenue catalyst. The key unresolved variable is balance sheet runway, which is not disclosed in the supplied income statement data; without visibility into cash and cash equivalents, the pace of future dilution or program divestiture cannot be reliably assessed.